This is a randomized, double-blind, placebo-controlled, multicenter Phase III study evaluating the efficacy and safety of orelabrutinib in patients with SLE, with the SRI-4 response rate at Week 52 as ...
Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...
In a new analysis of Phase 2 and 3 anifrolumab (Saphnelo®) clinical trial data, researchers found that the SLE Disease ...
Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...
The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...
Please provide your email address to receive an email when new articles are posted on . SLE-DAS remission and low disease activity discriminated between patients taking active drug vs. placebo. Both ...
The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing SLE is one of the most prevalent and ...
Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results